Works matching Cirrhosis of the liver

Results: 5000
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Abordaje de la desnutrición en pacientes hospitalizados con diabetes/hiperglucemia y cirrosis hepática.

    Published in:
    Nutrición Hospitalaria, 2022, v. 39, p. 47, doi. 10.20960/nh.04511
    By:
    • Matía-Martín, Pilar;
    • González-Sánchez, Víctor;
    • Burgos, Rosa;
    • Manuel García-Almeida, José;
    • Palma, Samara;
    • Sanz-Paris, Alejandro;
    • Zugasti, Ana;
    • Joaquín Alfaro-Martínez, José;
    • Artero Fullana, Ana;
    • Calañas-Continente, Alfonso;
    • Jesús Chinchetru, María;
    • García Malpartida, Katherine;
    • González Díaz-Faes, Ángela;
    • Laínez López, María;
    • Serrano Moreno, Clara;
    • Martínez Ortega, Antonio Jesús;
    • Suárez Llanos, José Pablo;
    • Olivar Roldán, Juana
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33

    Copaiba Oleoresin Improves Weight Gain and IL-10 Concentration, with No Impact on Hepatic Histology, in Liver Cirrhosis Copaifera sp. is a native tree in the Amazon region. Copaiba oleoresin has components such as sesquiterpenes, which have anti-inflammatory and antioxidant potential. Liver cirrhosis is the end stage of liver disease with limited therapeutic options. We aimed to evaluate the effect of copaiba oleoresin supplementation on the liver of animals with thioacetamide (TAA)-induced cirrhosis. For the induction of liver cirrhosis, 100 mg/kg of TAA was administered intraperitoneally twice a week for 8 weeks. A total of 200 mg/kg/day of copaiba oleoresin was administered via gavage for the same period. Copaiba oleoresin supplementation improved cirrhosis-associated cachexia by increasing weight gain and body fat. In addition, copaiba oleoresin attenuated systemic inflammation, as shown by the decrease in the circulating C-reactive protein. In the liver, the copaiba oleoresin decreased carbonyl proteins and increased IL-10 compared with TAA-treated rats. TAA groups demonstrated increased SOD, catalase, GST, and GSH activity in the liver. In conclusion, the supplementation of copaiba oleoresin demonstrated a beneficial systemic effect in alleviating cirrhotic cachexia and antioxidant and anti-inflammatory action in the liver. However, it failed to improve the serological and histological markers of liver damage, which could be associated with the advanced stage of the disease.

    Published in:
    Biology (2079-7737), 2024, v. 13, n. 11, p. 853, doi. 10.3390/biology13110853
    By:
    • Taffarel, Maiara;
    • Silva, Bianca Sulzbacher da;
    • Paulino, Angélica Macedo Borgês;
    • Telles, Luciana Ortega;
    • Mendonça, Sabrina Trigueiro;
    • Santos, Cintia Vieira dos;
    • Giordani, Morenna Alana;
    • Nascimento, André Ferreira;
    • Aguiar, Danilo Henrique;
    • Sinhorin, Valéria Dornelles Gindri;
    • Andrighetti, Carla Regina;
    • Luvizotto, Renata de Azevedo Melo;
    • Bomfim, Gisele Facholi
    Publication type:
    Article
    34
    35
    36

    Evidence-based clinical practice guidelines for liver cirrhosis 2015.

    Published in:
    2016
    By:
    • Fukui, Hiroshi;
    • Saito, Hidetsugu;
    • Ueno, Yoshiyuki;
    • Uto, Hirofumi;
    • Obara, Katsutoshi;
    • Sakaida, Isao;
    • Shibuya, Akitaka;
    • Seike, Masataka;
    • Nagoshi, Sumiko;
    • Segawa, Makoto;
    • Tsubouchi, Hirohito;
    • Moriwaki, Hisataka;
    • Kato, Akinobu;
    • Hashimoto, Etsuko;
    • Michitaka, Kojiro;
    • Murawaki, Toshikazu;
    • Sugano, Kentaro;
    • Watanabe, Mamoru;
    • Shimosegawa, Tooru
    Publication type:
    journal article
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50